Virta revenue mix shifting to obesity
Virta Health
The mix shift shows Virta is becoming less of a single high priced diabetes vendor and more of a broader metabolic spend manager for employers. The diabetes reversal product still anchors contracts with higher pricing and stronger retention, but obesity is now the faster entry point because employers need cheaper alternatives to open ended GLP-1 spend. That expands Virta’s market, while pulling average revenue per patient down as lower priced obesity revenue grows.
-
Virta’s core diabetes product is sold like a high touch medical benefit, with connected devices, daily coaching, physician oversight, and fees tied to outcomes. That makes diabetes reversal the premium line, at about $2,808 in year 1, versus about $900 for obesity, so mix naturally moves downward on price as obesity scales.
-
The obesity product is growing because the buyer problem changed. Employers are facing rapid GLP-1 cost growth, and Virta can pitch a nutrition first program as a cheaper way to lower weight and slow drug utilization. New obesity signups are already growing faster than diabetes reversal, and weight loss now drives 45% of new enrollments.
-
This also changes who Virta competes with. In diabetes reversal, Virta wins on clinical intensity and premium contract value. In obesity, it moves closer to Omada, Noom, and GLP-1 management vendors, where larger markets come with lower ARPC and more pressure to prove savings at the employer account level.
From here, Virta is likely to keep shifting toward obesity and adjacent metabolic conditions, using diabetes reversal as the proof point and obesity as the scale engine. If it keeps showing employers lower GLP-1 trend and measurable claims savings, revenue should become more diversified, more recurring, and more tied to enterprise wide metabolic management rather than a single disease program.